UMINESCE: Phase 3 study of satralizumab, a therapeutic recycling antibody targeting the IL-6 receptor, in patients with generalised myasthenia gravis

被引：0
|
作者：
Kaminski, H. [1 ]
Zhao, C. [2 ]
zu Horste, G. Meyer [3 ]
O'Connor, K. [4 ]
Klingelschmitt, G. [5 ]
Krumova, P. [5 ]
Bolt, S. [6 ]
Vodopivec, I. [5 ]
Murai, H. [7 ]
机构：
[1] George Washington Univ, Washington, DC USA
[2] Fudan Univ, Shanghai, Peoples R China
[3] Univ Munster, Munster, Germany
[4] Yale Univ, New Haven, CT USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Roche Prod, Welwyn Garden City, Herts, England
[7] Univ Hlth & Welf, Narita, Japan
来源：
NEUROMUSCULAR DISORDERS | 2022年 / 32卷
关键词：
D O I：
10.1016/j.nmd.2022.07.162
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.92
引用
收藏
页码：S80 / S81
页数：2
相关论文
共 50 条
  • [1] LUMINESCE: A Phase 3 Study Evaluating Satralizumab, a Therapeutic Recycling Antibody Targeting the IL-6 Receptor, in Patients with Generalized Myasthenia Gravis
    Kaminski, Henry
    Zhao, Chongbo
    zu Hoerste, Gerd Meyer
    O'Connor, Kevin C.
    Klingelschmitt, Gaelle
    Krumova, Petranka
    Bolt, Stuart
    Vodopivec, Ivana
    Lennon-Chrimes, Sian
    Murai, Hiroyuki
    ANNALS OF NEUROLOGY, 2022, 92 : S199 - S199
  • [2] The prospect of therapeutic antibody targeting IL-6 receptor
    Nishimoto, Norihiro
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 27P - 27P
  • [3] Response to zilucoplan in the Phase 3 RAISE study in patients with generalised myasthenia gravis
    Mantegazza, R.
    Bresch, S.
    Freimer, M.
    Hewamadduma, C.
    Leite, M.
    Maniaol, A.
    Schmidt, J.
    Utsugisawa, K.
    Vu, T.
    Boroojerdi, B.
    Lejdstrom, R. Beau
    Duda, P.
    Grimson, F.
    Savic, N.
    Howard, J., Jr.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 207 - 208
  • [4] IL-6 attenuate the efficacy of treatment with glucocorticoid in the patients with myasthenia gravis
    Tanaka, S.
    Masuda, M.
    Minowa, Y.
    Ueta, Y.
    Hirano, T.
    Aizawa, H.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 907 - 907
  • [5] IL-6 receptor antibody treatment improves muscle weakness in experimental autoimmune myasthenia gravis mouse model
    Miyake, Shota
    Serizawa, Kenichi
    Onishi, Shinichi
    Katsura, Yoshichika
    Baba, Masayuki
    Kurasawa, Mitsue
    Tomizawa-Shinohara, Haruna
    Yorozu, Keigo
    Matsumoto, Yoshihiro
    Noguchi-Sasaki, Mariko
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [6] Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised double-blind, multicentre, placebo-controlled phase 3 trial
    Habib, Ali A.
    Zhao, Chongbo
    Aban, Inmaculada
    Franca Jr, Marcondes Cavalcante
    Jose, Jorge Gustavo
    Hoerste, Gerd Meyer zu
    Klimiec-Moskal, Elzbieta
    Pulley, Michael T.
    Tavolini, Dario
    Krumova, Petranka
    Lennon-Chrimes, Sian
    Smith, Jillian
    Thanei, Gian-Andrea
    Blondeau, Kathleen
    Vodopivec, Ivana
    Wolfe, Gil, I
    Murai, Hiroyuki
    LANCET NEUROLOGY, 2025, 24 (02): : 117 - 127
  • [7] Acetylcholine receptor antibody in myasthenia gravis: A study in north Chinese patients
    Qu Yuan
    Xie Yan-chen
    Li Haifeng
    Zhang Hua
    Sun Liang
    Zhu Xiao-quan
    Jiang Bin
    Wang Shu-hui
    Wang De-xin
    JOURNAL OF NEUROIMMUNOLOGY, 2010, 228 (1-2) : 178 - 179
  • [8] Polymorphisms at-174 and in the 3′ flanking region of interleukin-6 (IL-6) gene in patients with myasthenia gravis
    Huang, DR
    Zheng, CY
    Giscombe, R
    Matell, G
    Pirskanen, R
    Lefvert, AK
    JOURNAL OF NEUROIMMUNOLOGY, 1999, 101 (02) : 197 - 200
  • [9] The relationship between serum iron levels and AChR-Ab and IL-6 in patients with myasthenia gravis
    Huang, P.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (01) : 98 - 102
  • [10] Myasthenia gravis patients with low plasma IL-6 and IFN-γ benefit from etanercept treatment
    Tüzün, E
    Meriggioli, MN
    Rowin, J
    Yang, H
    Christadoss, P
    JOURNAL OF AUTOIMMUNITY, 2005, 24 (03) : 261 - 268
12345